7-Methylquinazolin-2-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 7-Methylquinazolin-2-amine
• 英文别名: 7-methylquinazolin-2-amine
• 化学式: C₉H₉N₃
• 分子量: 159.19
• InChiKey: DQUUJIDZGKRFCM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  51.8
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] COMPOUNDS TARGETING PRMT5<br/>[FR] COMPOSÉS CIBLANT PRMT5
  申请人：ALIGOS THERAPEUTICS INC

  公开号：WO2020205867A1

  公开（公告）日：2020-10-08

  Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

  本文提供了式（I）的化合物或其药用盐，包括含有本文描述的化合物（包括本文描述的化合物的药用盐）的药物组合物以及合成这些化合物的方法。本文还提供了使用式（I）的化合物或其药用盐治疗疾病和/或症状的方法。
• PYRIDOPYRIMIDINE COMPOUNDS ACTING AS MTORC 1/2 DOUBLE-KINASE INHIBITORS
  申请人：MEDSHINE DISCOVERY INC.

  公开号：US20200339568A1

  公开（公告）日：2020-10-29

  Disclosed are a series of pyridopyrimidine compounds and a use of same in the preparation of drugs associated with mTORC 1/2 dual complex inhibitors, and specifically disclosed is a use of the compounds as shown in formula (IV), tautomers thereof or pharmaceutically acceptable salts thereof in the preparation of drugs associated with mTORC 1/2 dual complex inhibitors.

  本文披露了一系列吡啶吡嘧啶化合物及其在制备与mTORC 1/2双复合物抑制剂相关的药物中的用途，具体披露了将所述化合物，其互变异构体或其药学上可接受的盐如公式（IV）所示用于制备与mTORC 1/2双复合物抑制剂相关的药物。
• [EN] METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION<br/>[FR] MÉTHODES ET COMPOSÉS POUR LA RESTAURATION D'UNE FONCTION DE MUTANTS DE P53
  申请人：PMV PHARMACEUTICALS INC

  公开号：WO2021262596A1

  公开（公告）日：2021-12-30

  Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods that restore DNA binding affinity of p53 mutants. The compounds of the present disclosure can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

  癌基因和肿瘤抑制基因的突变促进了癌症的发展和进展。本公开描述了一种恢复p53突变体DNA结合亲和力的化合物和方法。本公开的化合物可以结合突变的p53，并恢复p53突变体结合DNA和激活与肿瘤抑制有关的下游效应子的能力。公开的化合物可用于减少含有p53突变的癌症的进展。
• Pyridopyrimidine compounds acting as mTORC 1/2 dual inhibitors
  申请人：MEDSHINE DISCOVERY INC.

  公开号：US11377444B2

  公开（公告）日：2022-07-05

  Disclosed are a series of pyridopyrimidine compounds and a use of same in the preparation of drugs associated with mTORC 1/2 dual complex inhibitors, and specifically disclosed is a use of the compounds as shown in formula (IV), tautomers thereof or pharmaceutically acceptable salts thereof in the preparation of drugs associated with mTORC 1/2 dual complex inhibitors.

  公开了一系列吡啶嘧啶化合物及其在制备与mTORC 1/2双重复合体抑制剂相关的药物中的用途，特别公开了如式（IV）所示的化合物、其同系物或其药学上可接受的盐在制备与mTORC 1/2双重复合体抑制剂相关的药物中的用途。